Australia Cuts Reimbursement Decision Times & Boosts Submission Success Rates
Executive Summary
Collaboration between the health department and the pharmaceutical industry on improvements to the reimbursement listing process has led to a fall in the average time to listing and a higher success rate for first-time submissions, says a new report.
You may also be interested in...
EU Adopts New Rules On UK-Wide Approvals For Novel Drugs
Having been passed by the European Parliament and now the Council of the EU, new legislation will clear up some of the issues raised by Brexit relating to trade in medicines between Great Britain and Northern Ireland.
UK In Major Move To Boost Commercial Clinical Trials & Improve Life Sciences Environment
The publication of two major reports has led the UK government to announce a £650m “Life Sci for Growth” package to bolster the life sciences sector.
UK Reveals Seven Partners Whose New Drug Approvals It Will Recognize
The UK regulator, the MHRA, says that while it will recognize drug approvals granted in the EU and a selection of other countries, it will remain a “sovereign regulator” with the ability to reject applications if they don’t meet its standards.